Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news

Show

From To
Fixed-dose regimes ‘modestly’ lower risk of HIV treatment failure

New research compares treatment outcomes of single versus multiple tablet regimes, raising questions around cost-effectiveness.

Published
10 hours ago
From
Avert
Could we safely reduce the frequency of treatments for HIV-positive people?

Most HIV-positive people in France under treatment take a daily dose of antiviral drugs for life. However, a major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.

Published
08 December 2017
From
The Conversation
People with HIV more likely to adhere to their antiretroviral therapy than treatment for other chronic health problems

Ageing HIV-positive people have significantly higher levels of adherence to their antiretroviral therapy than to medication taken for other chronic health problems, Swiss investigators report in HIV Medicine. The

Published
07 November 2017
By
Michael Carter
Drug interaction concerns may negatively affect HIV treatment adherence among transgender women

Participants in NIH-supported study apprehensive about combining HIV medications and hormones.

Published
25 July 2017
From
NIAID
Less frequent clinic visits for HIV care: fine tuning needed

Shifts to less frequent clinic visits and medication pick-ups to free up healthcare resources and make life easier for people living with HIV are being implemented successfully

Published
24 July 2017
By
Keith Alcorn
Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks

Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable

Published
24 July 2017
By
Liz Highleyman
HIV drug resistance testing not a priority for resource-limited settings, trial finds

Resistance testing is unlikely to improve the effectiveness of second-line HIV treatment in resource-limited settings and the introduction of routine HIV drug resistance testing is

Published
14 June 2017
By
Keith Alcorn
SA's new HIV challenge: patients who believe they've been healed

On the eve of South Africa’s national AIDS conference taking place in Durban this week, it has emerged that people are defaulting on their ARVs – often under the impression that they have been healed. According to health workers Health-e News spoke to, the issue relates to the “undetectable viral load” diagnosis patients receive when their antiretroviral therapy starts working and causes the amount of virus in their blood to drop to an extremely low level.

Published
13 June 2017
From
Citizen
Agreements with cash incentives boost patient adherence to HIV therapy and rates of viral suppression

People who enter into a contract with their HIV healthcare provider to receive cash incentives in return for high levels of antiretroviral therapy (ART) adherence are more

Published
30 May 2017
By
Michael Carter
Nurse-led intervention improves adherence to ART and is cost-effective

An antiretroviral therapy (ART) adherence support study conducted in the Netherlands has been hailed as “an outstanding addition to the scientific literature on adherence.” Published

Published
28 March 2017
By
Michael Carter
← First12345...39Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.